Xia Wei, Li Sun, Eric Slade, Caitlin T Fierheller, Samuel Oxley, Ashwin Kalra, Jacqueline Sia, Michail Sideris, W Glenn McCluggage, Nathan Bromham, Katharina Dworzynski, Adam N Rosenthal, Adam Brentnall, Stephen Duffy, D Gareth Evans, Li Yang, Rosa Legood, Ranjit Manchanda
IMPORTANCE: Pathogenic variants (PVs) in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1 cancer susceptibility genes (CSGs) confer an increased ovarian cancer (OC) risk, with BRCA1, BRCA2, PALB2, RAD51C, and RAD51D PVs also conferring an elevated breast cancer (BC) risk. Risk-reducing surgery, medical prevention, and BC surveillance offer the opportunity to prevent cancers and deaths, but their cost-effectiveness for individual CSGs remains poorly addressed. OBJECTIVE: To estimate the cost-effectiveness of prevention strategies for OC and BC among individuals carrying PVs in the previously listed CSGs...
February 5, 2024: JAMA Network Open